2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135388
    ent-Ezetimibe 1376614-99-1 98%
    ent-Ezetimibe (ent-SCH 58235) is the RRS-enantiomer of Ezetimibe. Ezetimibe is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    ent-Ezetimibe
  • HY-135402
    2'-Ethyl Simvastatin 79902-42-4 98%
    2'-Ethyl Simvastatin (compound 6) is a Mevinolin analog, with HMG-CoA reductase inhibition.
    2'-Ethyl Simvastatin
  • HY-135404
    Anhydrosimvastatin 210980-68-0 98%
    Anhydrosimvastatin (Impurity C) is an impurity of Simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase.
    Anhydrosimvastatin
  • HY-135405
    4-Acetylsimvastatin 145576-25-6 98%
    4-Acetylsimvastatin is an acetylated simvastatin. Simvastatin is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    4-Acetylsimvastatin
  • HY-135406
    (3R,5R)-Rosuvastatin Lactone 1422954-11-7 98%
    (3R,5R)-Rosuvastatin Lactone is an isomer of Rosuvastatin Lactone.
    (3R,5R)-Rosuvastatin Lactone
  • HY-135408
    Trimetazidine-N-oxide 1644530-89-1 98%
    Trimetazidine-N-oxide is the major active metabolite of Trimetazidine. Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM. Trimetazidine is an effective antianginal agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties.
    Trimetazidine-N-oxide
  • HY-135501
    Bamifylline 2016-63-9 98%
    Bamifylline is a drug in the chemical class of xanthine that acts as a selective adenosine A1 receptor antagonist.
    Bamifylline
  • HY-135541
    Darexaban maleate 365462-24-4 98%
    Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K(m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K(m) value of 27.3 μM. The unbound K(m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9.
    Darexaban maleate
  • HY-135562
    Ascofuranone 38462-04-3 98%
    Ascofuranone, a prenylphenol antibiotic, is a potent and selective trypanosome alternative oxidase (TAO) inhibitor. Ascofuranone has inhibitory activity against human dihydroorotate dehydrogenase (DHODH). Ascofuranone has diverse physiological activities, including antibiotic, hypolipidemic, anti-inflammatory, and anti-cancer.
    Ascofuranone
  • HY-135571
    VBIT-3 2088463-66-3 98%
    VBIT-3 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 31.3 μM. VBIT-3, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases.
    VBIT-3
  • HY-135601
    Cinacalcet metabolite M4 104774-87-0 98%
    Cinacalcet metabolite M4 is a metabolite of Cinacalcet. Cinacalcet is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease.
    Cinacalcet metabolite M4
  • HY-135773
    CRTh2 antagonist 3 312928-72-6 98%
    CRTh2 antagonist 3 is a potent chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist. CRTh2 antagonist 3 enhances the activity of PDK1 toward a short peptide substrate, with an EC50 of 2 μM and a Kd of 8.4 μM. CRTh2 antagonist 3 has the potential for cardiovascular inflammation.
    CRTh2 antagonist 3
  • HY-136059
    Desfluoro-ezetimibe 302781-98-2 98%
    Desfluoro-ezetimibe is a desfluoro impurity of Ezetimibe. Ezetimibe is a potent, metabolically stable cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    Desfluoro-ezetimibe
  • HY-136347
    3α-Hydroxy pravastatin sodium 81093-43-8 99.35%
    3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin. Pravastatin is a competitive HMG-CoA reductase inhibitor.
    3α-Hydroxy pravastatin sodium
  • HY-136501
    MRS2395 491611-55-3 98%
    MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a Ki of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC50 of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6.
    MRS2395
  • HY-136511
    Epicaptopril 63250-36-2 98%
    Epicaptopril (SQ 14534) is the derivative of Captopril (HY-B0368). Epicaptopril is an inhibitor for angiotensin-converting enzyme (ACE). Epicaptopril enhances vasodilation in an endothelium-derived relaxing factor (EDRF)-dependent manner. Epicaptopril is a free radical scavenger, and can be used in research about oxidative stress and free radical damage caused cardiovascular disorders.
    Epicaptopril
  • HY-136625
    LY134046 71274-97-0 98%
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
    LY134046
  • HY-136677
    Lnd 796 118549-42-1 98%
    LND 796 is an aminosteroidal derivative with positive inotropic effects similar to those of digitalis. It exhibits electrophysiological, toxic, and inotropic effects in normal and partially potassium-depolarized ventricular muscles. LND 796 requires higher concentrations than digoxin to induce the same toxic symptoms. It exhibits a concentration-dependent positive inotropic effect on guinea pig papillary muscles in normal potassium solution. In partially potassium-depolarized papillary muscles, LND 796 enhances both components of contraction and increases the amplitude of slow action potentials. The mechanism of positive inotropic action of LND 796 involves enhanced calcium entry in calcium channels and inhibition of sodium-potassium ATPase. Due to its expanded positive inotropic range, LND 796 may have potential application in the treatment of congestive heart failure.
    Lnd 796
  • HY-136791
    BN52115 120908-94-3 98%
    BN 52115, a platelet-activating factor antagonist, has demonstrated the ability to mitigate bronchopulmonary changes in vivo.
    BN52115
  • HY-136901
    Fusarochromanone 802915-53-3 98%
    Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS).
    Fusarochromanone
Cat. No. Product Name / Synonyms Application Reactivity